Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737151 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer
A NA study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01737151: Clinical Trial NA study, sponsored by Virginia Commonwealth University.
NCT01737151 is a NA study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 19 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01737151, a NA study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
Primary Outcome
Will be tested using a continuity corrected chi-square test
Interventions
- RADIATION stereotactic body radiation therapy
- RADIATION four fraction split-course SBRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-03-08 |
| Est. Completion | 2017-11-09 |
| Phase | NA |
Why NCT01737151 stopped before completion
NCT01737151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which stereotactic body radiation therapy is the first listed.
NCT01737151 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01737151 about?
NCT01737151 is a clinical study titled "Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer". This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
What is the current status of trial NCT01737151?
This trial is currently terminated. It is a NA study. The enrollment target is 19 participants. The study started on 2013-03-08. Estimated completion is 2017-11-09.
What interventions are being tested in trial NCT01737151?
The interventions under investigation include: stereotactic body radiation therapy (RADIATION), four fraction split-course SBRT (RADIATION).
Who is sponsoring clinical trial NCT01737151?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01737151's enrollment target sits among peer trials
19 1861st of 2000 higher than 138 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI